Four-Drug attack on advanced head & neck cancer begins human testing
NCT ID NCT06509009
Summary
This study is testing a new combination of four drugs as the first treatment for people whose nasopharyngeal cancer (a type of head and neck cancer) has returned or spread. The goal is to see if adding two targeted drugs (nimotuzumab and toripalimab) to standard chemotherapy (gemcitabine and cisplatin) is more effective and safe. The trial will enroll 30 participants to measure how well the tumors shrink and how long the treatment keeps the cancer from growing.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NASOPHARYNGEAL CARCINOMA BY AJCC V8 STAGE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medcial Science and Peking Union Medical College
RECRUITINGBeijing, Beijing Municipality, 1000000, China
Conditions
Explore the condition pages connected to this study.